A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy

We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3(rd) generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Ann Transl Med
Auteurs principaux: Hirakawa, Haruki, Komiya, Kazutoshi, Nakashima, Chiho, Ogusu, Shinske, Nakamura, Tomomi, Tanaka, Masahide, Takahashi, Koichiro, Egashira, Yoshiaki, Kai, Keita, Kimura, Shinya, Sueoka-Aragane, Naoko
Format: Artigo
Langue:Inglês
Publié: AME Publishing Company 2018
Sujets:
Case Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6312808/
https://ncbi.nlm.nih.gov/pubmed/30603652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2018.11.25
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires